Patient characteristics at RESPITE baseline (the last documented value while still receiving phosphodiesterase-5 inhibitor)

CharacteristicRiociguat up to 2.5 mg t.i.d. (n=61)
Female45 (74)
Caucasian56 (92)
BMI kg·m−228±5
Dana Point classification of PH
 1.1 Idiopathic PAH56 (92)
 1.2 Heritable PAH1 (2)
 1.3 Drug- or toxin-induced PAH1 (2)
 1.4 PAH associated with congenital heart disease2 (3)
 1.4 PAH associated with connective tissue disease#1 (2)
Concomitant treatment with ERA50 (82)
Pretreated with sildenafil40 (66)
Pretreated with tadalafil21 (34)
Concomitant diuretic use45 (74)
Time since first PH diagnosis years4±4
6MWD m357±81
WHO FC III61 (100)
NT-proBNP pg·mL−11190±1828
eGFR mL·min−1·1.73 m−273±22
PVR dyn·s·cm–5835±272
Cardiac output L·min−14.2±0.8
Cardiac index L·min−1·m−22.3±0.4
mPAP mmHg52±12
RAP mmHg8.3±4.9
SvO2 %64.8±6.9
SVR+ dyn·s·cm–51624±452
PAWP mmHg9.4±3.2
SBP mmHg118±15
DBP mmHg72±9
Heart rate beats per min75±11

Data are presented as n (%) or mean±sd, unless otherwise stated. #: protocol violation; patient randomised due to investigator error; : n=58; +: n=60. BMI: body mass index; PH: pulmonary hypertension; PAH: pulmonary arterial hypertension; ERA: endothelin receptor antagonist; 6MWD: 6-min walking distance; WHO FC: World Health Organization functional class; NT-proBNP: N-terminal prohormone of brain natriuretic peptide; eGFR: estimated glomerular filtration rate; PVR: pulmonary vascular resistance; mPAP: mean pulmonary arterial pressure; RAP: right atrial pressure; SvO2: mixed venous oxygen saturation; SVR: systemic vascular resistance; PAWP: pulmonary artery wedge pressure; SBP: systolic blood pressure; DBP: diastolic blood pressure.